Abstract
Abstract 36 a pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Catherine Turkel, PharmD (Allergan Inc, Irvine, CA); Beta Bowen, MS; Jingyu Liu, PhD; Mitchell Brin, MD, e-mail: turkel_catherine@allergan.com
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
